Business Context and Reporting Period
Company: NeuroOne Medical Technologies Corp (NMTC)
Filing Type: Form 8-K (Current Report)
Date of Report: May 21, 2026
Subject: Non-reliance on previously issued financial statements for the quarter ended March 31, 2026, due to accounting errors.
Key Financial Metrics and Adjustments
The filing discloses preliminary estimates of accounting errors affecting the quarter and six months ended March 31, 2026. The previously reported figures are to be restated as follows:
- Revenue: Overstated by approximately $529,000.
- Accounts Receivable: Overstated by approximately $529,000.
- Gross Profit: Overstated by approximately $296,000.
- Operating Loss and Net Loss: Understated by approximately $296,000 (meaning losses were higher than reported).
- Total Assets: Overstated by approximately $296,000 as of March 31, 2026.
- Inventory: Understated by approximately $233,000 as of March 31, 2026.
Note: This filing does not provide the original reported revenue, profit, cash flow, or debt figures, only the magnitude of the required adjustments.
Material Changes and Causes
The material changes stem from accounting errors related to revenue recognition. The root cause was identified as the inadequate design and implementation of internal controls and procedures to evaluate certain customer modified purchase orders. The Audit Committee determined that the interim financial statements in the Form 10-Q filed on May 12, 2026, should no longer be relied upon. The company states these matters did not involve intentional misconduct.
Outlook, Risks, and Management Commentary
- Restatement Plan: The Company intends to file an amendment to the Form 10-Q to restate unaudited condensed financial statements and amend the Management's Discussion and Analysis (MD&A).
- Timing: The amendment will be filed "as soon as reasonably practicable."
- External Review: The Audit Committee and management have discussed the errors with the independent registered public accounting firm, Baker Tilly US, LLP.
- Risks: The estimates provided are preliminary and subject to change upon completion of the financial review. Forward-looking statements regarding the timing and impact of the restatement involve risks and uncertainties.
Investor Verification Checklist
- Verify the upcoming amended Form 10-Q for the quarter ended March 31, 2026, to confirm final restated figures.
- Review the specific details of the internal control deficiencies regarding customer modified purchase orders.
- Monitor for any further disclosures regarding the impact on liquidity or debt covenants resulting from the restated asset and loss figures.
- Confirm the timeline for the filing of the amendment to the Previous Filing.